Literature DB >> 12831924

Neurorrhaphy of the recurrent laryngeal nerve.

Fong-Fu Chou1, Chih-Ying Su, Seng-Feng Jeng, Kuan-Long Hsu, Kei-Yun Lu.   

Abstract

BACKGROUND: It has been controversial to anastomose the severed recurrent laryngeal nerve after transection because when severed recurrent nerves are directly anastomosed, the vocal cords do not regain normal movements and are fixed in the median. The objective of this study was to learn whether direct neurorrhaphy is necessary if the recurrent laryngeal nerve is severed during thyroid or parathyroid surgery. STUDY
DESIGN: From 1998 to 2001, 12 patients who had a complete recurrent laryngeal nerve injury during thyroid or parathyroid surgery were enrolled into this study. Eight had primary repair of the nerve; four did not have repair because of cancer invasion. Patients were followed with laryngoscopic or laryngovideostroboscopic examination at 3 months and 6 months postoperatively. Subjective ratings of aspiration and voice quality were based on patient reports. Perceptual voice quality was rated according to grade, roughness, breathiness, asthenia, and strain (GRBAS) scales. If a patient's voice quality, aspiration, and GRBAS scales did not improve at 6 months postoperatively, medialization laryngoplasty was considered.
RESULTS: Eight patients with immediate repair showed improved voice quality, aspiration, GRBAS scales, and maximum phonation time at 6 months after surgery. A significant decrease of glottal gap was also noted in patients with neurorrhaphy but not in four patients without neurorrhaphy. Medialization laryngoplasty was performed in all four patients without neurorrhaphy in the followup period. Immobilization of the vocal cord was noted in all of them, but only one in the neurorrhaphy group had an atrophy of the cord; all four patients without neurorrhaphy had atrophy.
CONCLUSIONS: Neurorrhaphy of the recurrent laryngeal nerve is a simple and effective procedure to improve voice quality, aspiration, GRBAS scales, glottal gap, and maximum phonation time by preventing atrophy of the vocal cord.

Entities:  

Mesh:

Year:  2003        PMID: 12831924     DOI: 10.1016/S1072-7515(03)00235-7

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  7 in total

1.  Selective recurrent laryngeal nerve stimulation using a penetrating electrode array in the feline model.

Authors:  Yarah M Haidar; Ronald Sahyouni; Omid Moshtaghi; Beverly Y Wang; Hamid R Djalilian; John C Middlebrooks; Sunil P Verma; Harrison W Lin
Journal:  Laryngoscope       Date:  2017-10-31       Impact factor: 3.325

Review 2.  A narrative review of current therapies in unilateral recurrent laryngeal nerve injury caused by thyroid surgery.

Authors:  Hedi Tian; Jun Pan; Linghui Chen; Yijun Wu
Journal:  Gland Surg       Date:  2022-01

3.  Comparison of vocal outcome following two different procedures for immediate RLN reconstruction.

Authors:  Yoshihiko Kumai; Narihiro Kodama; Daizo Murakami; Eiji Yumoto
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-14       Impact factor: 2.503

4.  Head injury patient with bilateral vocal cord paralysis: a mistake and a lesson learnt.

Authors:  Gaurav Singh Tomar; Niraj Kumar; Anudeep Saxena; Keshav Goyal
Journal:  BMJ Case Rep       Date:  2015-11-18

5.  Laryngeal reinnervation using ansa cervicalis for thyroid surgery-related unilateral vocal fold paralysis: a long-term outcome analysis of 237 cases.

Authors:  Wei Wang; Donghui Chen; Shicai Chen; Ding Li; Meng Li; Siwen Xia; Hongliang Zheng
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

6.  Reconstructive procedures for impaired upper airway function: laryngeal respiration.

Authors:  Andreas Müller
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

7.  Laryngeal adductor function following potassium titanyl phosphate laser welding of the recurrent laryngeal nerve.

Authors:  Neel K Bhatt; Brian T Faddis; Randal C Paniello
Journal:  Laryngoscope       Date:  2019-09-30       Impact factor: 2.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.